These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1396 related articles for article (PubMed ID: 11642606)

  • 1. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H; Shu S
    J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
    Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
    Korbelik M; Dougherty GJ
    Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z; Fan H; Wu Y; Chen B
    Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.